

UC Davis

UC Davis Previously Published Works

Title

Epigenetics may characterize asymptomatic COVID-19 infection

Permalink

<https://escholarship.org/uc/item/8wt707q9>

Journal

Human Genomics, 16(1)

ISSN

1473-9542

Authors

Arnold, Cosby G

Konigsberg, Iain

Adams, Jason Y

et al.

Publication Date

2022-12-01

DOI

10.1186/s40246-022-00401-3

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

CORRESPONDENCE

Open Access



Epigenetics may characterize asymptomatic COVID-19 infection

Cosby G. Arnold^{5*}, Iain Konigsberg², Jason Y. Adams³, Sunita Sharma⁴, Neil Aggarwal⁴, Andrew Hopkinson¹, Alexis Vest¹, Monica Campbell², Meher Boorgula², Ivana Yang^{2†}, Christopher Gignoux^{2†}, Kathleen C. Barnes^{2†} and Andrew A. Monte¹

Abstract

RT-PCR is the foremost clinical test for diagnosis of COVID-19. Unfortunately, PCR-based testing has limitations and may not result in a positive test early in the course of infection before symptoms develop. Enveloped RNA viruses, such as coronaviruses, alter peripheral blood methylation and DNA methylation signatures may characterize asymptomatic versus symptomatic infection. We used Illumina's Infinium MethylationEPIC BeadChip array to profile peripheral blood samples from 164 patients who tested positive for SARS-CoV-2 by RT-PCR, of whom 8 had no symptoms. Epigenome-wide association analysis identified 10 methylation sites associated with infection and a quantile–quantile plot showed little inflation. These preliminary results suggest that differences in methylation patterns may distinguish asymptomatic from symptomatic infection.

Keywords: SARS-CoV-2, COVID-19, Methylation, Epigenetics

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to represent an exceptional challenge for medicine and society. As of June 2022, there were more than 532 million confirmed cases worldwide with almost one fifth of these in the U.S.A [1]. Coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, has a wide spectrum of severity with many infected individuals showing only mild or no symptoms [2]. The current testing strategy in the U.S. is limited primarily to symptomatic patients, an approach that fails to recognize the critical need for screening and surveillance. By waiting until patients progress to develop symptoms of COVID-19, we may be missing a critical

intervention period. Understanding the epidemiology of asymptomatic and minimally symptomatic infection may have important implications for public health, including contact tracing, quarantine, and prediction of clinical outcomes.

Tests for SARS-CoV-2 infection based on reverse transcriptase polymerase chain reaction (RT-PCR) have limitations. PCR-based testing offers little diagnostic utility early after exposure, termed a “window period” after acquisition of infection [3]. Epigenetic markers reveal the underlying biology and can improve early diagnosis and risk stratification. Enveloped RNA viruses such as coronaviruses can manipulate the host's epigenome via DNA methylation and thereby facilitate the identification of SARS-CoV-2 infected patients prior to symptom onset [4]. Moreover, these epigenetic patterns can differentiate patients who progress to severe disease [5]. This technology has the potential to optimize treatment and disposition decisions. In this study, we leveraged the Illumina Infinium MethylationEPIC BeadChip to evaluate DNA

[†]Ivana Yang, Christopher Gignoux and Kathleen C. Barnes equally contributing senior author

*Correspondence: cgarnold@ucdavis.edu

⁵ Department of Emergency Medicine, University of California, Davis, Sacramento, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

methylation patterns in asymptomatic and symptomatic SARS-CoV-2 infected patients.

Materials and methods

We performed a case–control epigenome-wide association study (EWAS) to characterize asymptomatic versus symptomatic SARS-CoV-2 infection. This study was a sub-analysis of a larger study that described methylation patterns associated with COVID-19 severity, and the methods outlined here are as described previously [5].

All patients aged 18 years or older who presented to the University of Colorado Hospital from 1 March 2020 to 31 July 2020 and received a SARS-CoV-2 test by RT-PCR for any reason were eligible for this study (e.g., prior to hospitalization for COVID-19, surgical procedures, routine hospitalization, return to work clearance). Cases were defined as those who tested positive for SARS-CoV-2 by RT-PCR but had no symptoms; symptomatic patients with a positive test result served as controls. We tested peripheral blood DNA samples with the Illumina Infinium MethylationEPIC BeadChip and abstracted clinical data from the associated clinical visit from the electronic health record (EHR). All patients were followed across the University of Colorado Health (UCHealth) System over time for a minimum of 3 months to determine presence of symptoms at the time of the blood draw and to determine development and severity of symptoms and clinical outcomes (e.g., ED discharge, hospital admission, ICU, death).

DNA was extracted on the bead-based, automated extraction Maxwell[®] RSC System (Promega) and quantified using absorbance (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA) and fluorescence-based methods (Qubit; Thermo fisher Scientific, Waltham, MA). DNA quality was assessed with Agilent TapeStation (Agilent, Santa Clara, CA). Biospecimens were then uploaded to the Colorado Anschutz Research Genetics Organization (CARGO) laboratory information management system (LIMS).

Purified DNA samples were processed with Zymo EZ-96 DNA Methylation bisulfite conversion kits (Zymo, Irvine, CA). Random hexamer priming and Phi29 DNA polymerase were used for whole-genome amplification, and amplification products were enzymatically fragmented, purified from dNTPs, primers, and enzymes, and applied to the EPIC BeadChip.

EWAS analyses were performed on the entire epigenotyped dataset. Preprocessing and association testing was performed with the GLINT package. We used EPISTRU CTURE and ReFACTor to estimate components to adjust

for population structure and to account for cell-type proportions, respectively. A linear mixed-effects model was fit to each probe and adjusted for age, sex, chip position, 6 ReFACTor components, 1 EPISTRU CTURE component, and a covariance matrix accounting for possible relatedness. Probes were annotated to CpG islands and genic regions with annotatr.


The study protocol was approved by the Colorado Multiple Institutional Review Board (COMIRB) and the research adheres to the ethical principles of research outlined in the U.S. Federal Policy for the Protection of Human Subjects. Patients were consented for blood collection and electronic health record (EHR) data abstraction through the University of Colorado COVID-19 Biorepository or the University of Colorado Emergency Medicine Specimen Biobank (EMSB). Raw data were generated at Health Data Compass and the Colorado Center for Personalized Medicine.

Results

We enrolled 8 asymptomatic cases and 156 symptomatic controls (Fig. 1). None of the asymptomatic patients returned with symptoms during the follow-up period or had documentation of symptom development in the medical record during follow-up. Among the symptomatic patients, median age was 50 years, 88 (56%) were male, 22 (14%) Black, 43 (28%) White, and 85 (54%) Hispanic or Latino. Among asymptomatic patients, median age was 39.5 years, 5 (63%) were male, 3 (38%) Black, 3 (38%) White, and 3 (38%) Hispanic or Latino). None of these demographic variables were statistically different between groups.

Analyses of clinical variables and disease severity are presented in Table 1. None of the asymptomatic patients required supplemental oxygenation or mechanical ventilation. Median overall oxygen saturation was higher in asymptomatic patients ($p=0.01$) and this difference persisted in a sub-analysis of patients on room air ($p=0.004$). The median oxygen flow rate among symptomatic patients requiring supplemental oxygen was 3 (IQR 2,5). Symptomatic patients had longer hospital stays and more frequently required intensive care unit (ICU) admission, although these observations did not reach statistical significance.

We found clear signal genome-wide (after adjusting for ~ 750,000 tests), with 10 5'-C-phosphate-G-3' nucleotides (CpGs) in immune and neurologic genes significant after false discovery rate (FDR) adjustment for multiple testing (Table 2). Furthermore, a quantile–quantile



plot shows little inflation (as well as clear signal), with a lambda of 1.045257 (being close to 1, indicating the absence of systematic inflation of p-values, with only inflation at the tail for likely true signal) (Fig. 2). There is a clear pattern of methylation associated with asymptomatic SARS-CoV2 infected patients.

Discussion

In the present study, we found that genome-wide patterns of DNA methylation differed in patients with asymptomatic and symptomatic infection with SARS-CoV-2. The genes identified as significant between asymptomatic versus symptomatic SARS-CoV-2 infected patients are expressed in a number of different tissues, from the skin to the central nervous system. Exactly how the differential expression of these genes interact to influence COVID-19 outcomes is unclear, although many have a role in immune function. A better understanding of COVID-19 epigenetics may help inform current

disparities in COVID-19 and facilitate early, targeted interventions.

Prior studies of symptomatic patients have identified differentially methylated genes that distinguish SARS-CoV-2 infection from non-COVID-19 respiratory illness and that are associated with COVID-19 disease severity [5–7]. To our knowledge, our study is the first to evaluate methylation patterns in asymptomatic patients. While genetic studies in COVID-19 have identified gene clusters on chromosome 3 that are associated with disease severity, genetics alone do not adequately explain the underlying biology of COVID-19 with regard to disease severity [8]. If future studies substantiate our findings, epigenetics may prove helpful in predicting the host response to SARS-CoV-2 infection, both in asymptomatic and symptomatic patients, enabling risk stratification and personalization of both pre-exposure and early post-exposure therapies. As a compliment to genetic studies, epigenetic analyses may provide a link between environmental exposures,

Table 1 Clinical characteristics of symptomatic and asymptomatic patients with COVID-19

	Symptomatic (n = 156)	Asymptomatic (n = 8)	P value
BMI	29.5 (25.4, 34.2)	35.7 (26.9, 37.4)	0.67
History of asthma	15 (9.68)	1 (12.50)	0.57
Heart rate	102.5 (90, 115)	94 (76, 127)	0.78
SpO ₂	92 (90, 95)	95.5 (94.5, 97)	0.01
Patients requiring supplemental oxygen	34 (24.46)	0 (0)	0.20
SpO ₂ in patients requiring supplemental oxygen	93 (90, 95)	NA	
SpO ₂ in patients on room air	92 (90, 95)	95.5 (94.5, 97)	0.004
Placed on ventilator	27 (17.53)	0 (0)	0.35
Admitted to ICU	43 (27.92)	1 (12.50)	0.68
ED disposition			0.58
Discharge	32 (20.65)	1 (12.50)	
Floor	101 (65.16)	7 (87.50)	
ICU	21 (13.55)	0 (0)	
Death	1 (0.65)	0 (0)	
Days in hospital	7 (3, 14)	5 (2, 6)	0.20
Final disposition			1
Home	114 (78.08)	7 (87.50)	
Nursing home or skilled rehabilitation	14 (9.59)	1 (12.50)	
Death	12 (8.22)	0 (0)	
Other	6 (4.11)	0 (0)	

Categorical variables, n (%); continuous variables, median (IQR)

SpO₂ oxygen saturation, ICU intensive care unit, ED emergency department

comorbidities, and infection with SARS-CoV-2 to enable a more complete understanding of the underlying biology.

Our analyses are limited by sample size and lack of follow-up outside the UHealth System after the index visit. The UHealth System cares for >50% of Coloradans across hundreds of clinics and 5 hospitals, but it remains possible that some asymptomatic patients could have developed mild symptoms without seeking care or been subsequently admitted with moderate-severe symptoms to a facility outside the UHealth System. Additionally, our cohort includes viral samples taken early in the pandemic. It is possible that infections with strains such as Delta and Omicron might be associated with different host epigenetics and subsequent research should investigate whether the loci associated with asymptomatic

illness in our study are strain specific or more broadly related to infection with SARS-CoV-2.


Conclusions

Our findings suggest that DNA methylation is altered in asymptomatic SARS-CoV-2 infected patients relative to symptomatic patients. These preliminary findings are based on a small sample size; additional data are needed to determine whether our findings are generalizable and if the epigenetic signatures we observed in asymptomatic patients are predictive of eventual outcomes. Existing genetic studies have not sufficiently explained COVID-19 disease severity [8]. Epigenetic signatures provide a link between the host and environmental exposure, in this

Table 2 Differential methylation patterns by gene location

Gene	Chromosomal location (hg19)	Gene function	Hypothetical clinical implications	β -coefficient	Difference in methylation (asymptomatic – symptomatic)	Q value*
F-box only protein 16 (FBXO16)	8.28302736	Promotes phosphorylation-dependent ubiquitination and degradation, involved in controlling amount of protein in eukaryotes	Degradation of beta-catenin leads to decreased cell adherent protein expression, leading to disruption of cardiac electrical and mechanical communication between myocytes	-0.23	-0.07	0.004
Pleckstrin and Sec7 domain containing 3 (PSD3)	8.18663702	Codes protein, involved in endocytosis, implicated in tumor suppression	Increases signal transduction targeting proteins to subcellular compartments to respond to viral infection	-0.14	-0.13	0.009
Ribonucleic acid export 1 (RAE1)	20.55953214	Nucleocytoplasmic transport, mitotic checkpoint regulator	This tumor suppressor gene may be important for cell division in immune cells	-0.20	-0.11	0.009
NIPA like domain containing 2 (NIPAL2)	8.99306708	Autosomal recessive gene associated with congenital ichthyosis	Involved in transport of glucose and other sugars, likely in response to increased metabolic demands of infection	-0.12	-0.13	0.019
SH3 and multiple ankyrin repeat domains 2 (SHANK2)	11.70681592	Codes postsynaptic proteins at excitatory synapses, disruption may predispose to autism or developmental delay	May play a role in SARS-CoV-2 induced altered mental status	-0.22	-0.05	0.023
Phosphoglucosyltransferase 1 (PGM1)	1.64117325	Codes isozyme of phosphoglucosyltransferase (PGM), mutations cause glycogen storage disease type 14, highly polymorphic, mutations causes glycogen storage disease	Associated with breakdown and synthesis of glucose, upregulated during acute infection due to metabolic demands	-0.15	-0.11	0.029

*We report q-values rather than p values. Q-values are adjusted using the Benjamini–Hochberg Procedure, which controls the false discovery rate (FDR). The raw p values do not account for the number of statistical tests being performed and, without correcting for multiple tests, there would be many false positives due to chance



case SARS-CoV-2 infection, which leads to additional insights into host-pathogen interactions. An epigenetic methylation pattern that characterizes asymptomatic infection could help optimize the treatment of asymptomatic patients and reduce resource utilization, as these patients could be counseled that they will remain asymptomatic and do not require treatment or follow-up.

Abbreviations

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019; RT-PCR: Reverse transcriptase polymerase chain reaction; EWAS: Epigenome-wide association study; EHR: Electronic health record; COMIRB: Colorado Multiple Institutional Review Board; EMSB: Emergency Medicine Specimen Biobank; FDR: False discovery rate.

Author contributions

CA and AM wrote the manuscript text and prepared the figures and tables. IK performed the statistical analyses. All authors provided a critical review of the manuscript. All authors read and approved the final manuscript.

Funding

Dr. Arnold is funded by NIH NHLBI 1F32HL160123. Dr. Monte is funded by NIH CTSA R35GM124939-01 and NIH CTSI TR001082. The epigenetic chips were donated in-kind by Illumina.

Availability of data and materials

De-identified data supporting the findings of this study are available from the corresponding author [CA] on request.

Declarations

Ethics approval and consent to participate

The study protocol was approved by the Colorado Multiple Institutional Review Board (COMIRB) and the research adheres to the ethical principles outlined in the U.S. Federal Policy for the protection of Human Subjects. Patients were consented for blood collection and electronic health record (EHR) data abstraction through the University of Colorado COVID-19 Biorepository or the University of Colorado Emergency Medicine Specimen Biobank (EMSB).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Emergency Medicine, University of Colorado – Anschutz Medical Campus, 12401 East 17th Avenue, 7th Floor, Aurora, CO 80045, USA. ²Division of Biomedical Informatics and Personalized Medicine, University of Colorado – Anschutz Medical Campus, 13001 East 17th Place, Campus Box C290, Aurora, CO 80045, USA. ³Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, 2835 J Street, Suite 400, Sacramento, CA 95816, USA. ⁴Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado – Anschutz Medical Campus, 12700 East 19th Avenue, Aurora, CO 9C0380045, USA. ⁵Department of Emergency Medicine, University of California, Davis, Sacramento, USA.

Received: 4 January 2022 Accepted: 1 July 2022

Published online: 27 July 2022

References

- Dong E, Du H, Gardner L. An interactive web-based dashboard to track covid-19 in real time. *Lancet Infect Dis.* 2020;20(5):533–4.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (Covid-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. *JAMA.* 2020.
- Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. *Ann Intern Med.* 2020;173(4):262–7.
- Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisefeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. *Proc Natl Acad Sci USA.* 2018;115(5):E1012–21.
- Konigsberg IR, Barnes B, Campbell M, Davidson E, Zhen Y, Pallisard O, et al. Host methylation predicts SARS-CoV-2 infection and clinical outcome. *Commun Med.* 2021;1(42):1–10.
- Balnis J, Madrid A, Hogan KJ, Drake LA, Chieng HC, Tiwari A, et al. Blood DNA methylation and Covid-19 outcomes. *Clin Epigenet.* 2021;13(1):118.
- Castro De Moura M, Davalos V, Planas-Serra L, Alvarez-Errico D, Arribas C, Ruiz M, et al. Epigenome-wide association study of Covid-19 severity with respiratory failure. *Ebiomedicine.* 2021;66:103339.
- Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Alballos A, Invernizzi P, et al. Genomewide association study of severe covid-19 with respiratory failure. *N Engl J Med.* 2020;383(16):1522–34.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

